Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 11/20 | 0.67 |
| ▸ | RORC | P51449 | 6/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4951165 | 0.86 | TRPV1 (0.66) | TRPV1SCN5ASCN9A | |
| SCHEMBL4808010 | 0.85 | RORC (0.59) | TRPV1RORCPPARG | |
| SCHEMBL4182281 | 0.84 | RORC (0.53) | TRPV1RORCPPARGSCN5ASCN9A | |
| SCHEMBL4811838 | 0.84 | TRPV1 (0.52) | TRPV1RORCPPARG | |
| SCHEMBL319915 | 0.79 | RORC (0.52) | TRPV1RORC | |
| SCHEMBL7920245 | 0.79 | PLA2G2D (0.49) | TRPV1RORCPPARGSCN5ASCN9A | |
| SCHEMBL3881337 | 0.77 | TRPV1 (0.65) | TRPV1RORCPPARG | |
| SCHEMBL13601671 | 0.76 | RORC (0.47) | TRPV1RORC | |
| SCHEMBL13601649 | 0.76 | RORC (0.49) | TRPV1RORCPPARG | |
| SCHEMBL6220196 | 0.75 | TRPV1 (0.49) | TRPV1SCN5ASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200535-A1 | sphingosine 1-phosphate-1/EDG-1 receptor agonists; autoimmune diseases; immunosuppressants by inducing lymphocyte sequestration in secondary lymphoid tissues; 4-aminocyclopentane-2-encarboxylic acid hydrochloric acid salt | ASAHI KASEI PHARMA CORPORATION (JP) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200535-A1 | sphingosine 1-phosphate-1/EDG-1 receptor agonists; autoimmune diseases; immunosuppressants by inducing lymphocyte sequestration in secondary lymphoid tissues; 4-aminocyclopentane-2-encarboxylic acid hydrochloric acid salt | S1PR1, S1PR2, S1PR4 | TRPV1 1004/4885RORC 171/4885PPARG 1029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.